Sex differences in aripiprazole sensitization from adolescence to adulthood

Elizabeth Freeman, Joanne Lin, Shinnyi Chow, Collin Davis, Ming Li

Research output: Contribution to journalArticle

Abstract

The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or clozapine (CLZ) using the conditioned avoidance response (CAR) and phencyclidine-induced (PCP) hyperlocomotion tests of antipsychotic activity. Male and female Sprague-Dawley adolescence rats (P46) were first treated with ARI (10 mg/kg) for 5 consecutive days (P46–50) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion. After they became adults (> P68), rats were challenged with ARI (1.5 mg/kg, sc) (P70), OLZ (0.5 mg/kg, sc; P73), CLZ (5 mg/kg, sc; P76) and again with ARI (1.5 mg/kg, sc; P84) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion again. During the drug treatment period in adolescence, repeated ARI treatment suppressed avoidance response, inhibited the PCP-induced hyperlocomotion, and these effects were progressively increased across the 5-day period in both males and females, confirming the induction of ARI sensitization. On the challenge days, rats previously treated with ARI in adolescence also had significantly lower avoidance and lower PCP-induced hyperlocomotion than the previous vehicle rats, confirming the expression of ARI sensitization and its persistence into adulthood. More importantly, female rats made significantly more avoidances than males in both ARI and vehicle groups, indicating higher sensitivity to the acute and long-term effects of ARI. Further, on the OLZ and CLZ challenge days, prior ARI treatment seemed to increase sensitivity to OLZ exposure, however, this increase was not significant. Similarly, rats also showed an ARI sensitization to OLZ and CLZ on challenge days. Collectively, results from this experiment demonstrated a sex difference in response to ARI and enhanced inhibition of PCP-induced hyperlocomotion in animals that were pretreated with ARI as compared to controls.

Original languageEnglish (US)
Pages (from-to)39-47
Number of pages9
JournalPharmacology Biochemistry and Behavior
Volume156
DOIs
StatePublished - May 1 2017

Fingerprint

Sex Characteristics
olanzapine
Rats
Clozapine
Aripiprazole
Drug therapy
Phencyclidine
Therapeutics
Antipsychotic Agents
Sprague Dawley Rats

Keywords

  • Aripiprazole
  • Conditioned avoidance response
  • Development
  • Phencyclidine
  • Sensitization
  • Sex difference

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

Sex differences in aripiprazole sensitization from adolescence to adulthood. / Freeman, Elizabeth; Lin, Joanne; Chow, Shinnyi; Davis, Collin; Li, Ming.

In: Pharmacology Biochemistry and Behavior, Vol. 156, 01.05.2017, p. 39-47.

Research output: Contribution to journalArticle

Freeman, Elizabeth ; Lin, Joanne ; Chow, Shinnyi ; Davis, Collin ; Li, Ming. / Sex differences in aripiprazole sensitization from adolescence to adulthood. In: Pharmacology Biochemistry and Behavior. 2017 ; Vol. 156. pp. 39-47.
@article{17aa5c63b09c4c83b5dcd9126bd0756a,
title = "Sex differences in aripiprazole sensitization from adolescence to adulthood",
abstract = "The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or clozapine (CLZ) using the conditioned avoidance response (CAR) and phencyclidine-induced (PCP) hyperlocomotion tests of antipsychotic activity. Male and female Sprague-Dawley adolescence rats (P46) were first treated with ARI (10 mg/kg) for 5 consecutive days (P46–50) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion. After they became adults (> P68), rats were challenged with ARI (1.5 mg/kg, sc) (P70), OLZ (0.5 mg/kg, sc; P73), CLZ (5 mg/kg, sc; P76) and again with ARI (1.5 mg/kg, sc; P84) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion again. During the drug treatment period in adolescence, repeated ARI treatment suppressed avoidance response, inhibited the PCP-induced hyperlocomotion, and these effects were progressively increased across the 5-day period in both males and females, confirming the induction of ARI sensitization. On the challenge days, rats previously treated with ARI in adolescence also had significantly lower avoidance and lower PCP-induced hyperlocomotion than the previous vehicle rats, confirming the expression of ARI sensitization and its persistence into adulthood. More importantly, female rats made significantly more avoidances than males in both ARI and vehicle groups, indicating higher sensitivity to the acute and long-term effects of ARI. Further, on the OLZ and CLZ challenge days, prior ARI treatment seemed to increase sensitivity to OLZ exposure, however, this increase was not significant. Similarly, rats also showed an ARI sensitization to OLZ and CLZ on challenge days. Collectively, results from this experiment demonstrated a sex difference in response to ARI and enhanced inhibition of PCP-induced hyperlocomotion in animals that were pretreated with ARI as compared to controls.",
keywords = "Aripiprazole, Conditioned avoidance response, Development, Phencyclidine, Sensitization, Sex difference",
author = "Elizabeth Freeman and Joanne Lin and Shinnyi Chow and Collin Davis and Ming Li",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.pbb.2017.04.001",
language = "English (US)",
volume = "156",
pages = "39--47",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Sex differences in aripiprazole sensitization from adolescence to adulthood

AU - Freeman, Elizabeth

AU - Lin, Joanne

AU - Chow, Shinnyi

AU - Davis, Collin

AU - Li, Ming

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or clozapine (CLZ) using the conditioned avoidance response (CAR) and phencyclidine-induced (PCP) hyperlocomotion tests of antipsychotic activity. Male and female Sprague-Dawley adolescence rats (P46) were first treated with ARI (10 mg/kg) for 5 consecutive days (P46–50) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion. After they became adults (> P68), rats were challenged with ARI (1.5 mg/kg, sc) (P70), OLZ (0.5 mg/kg, sc; P73), CLZ (5 mg/kg, sc; P76) and again with ARI (1.5 mg/kg, sc; P84) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion again. During the drug treatment period in adolescence, repeated ARI treatment suppressed avoidance response, inhibited the PCP-induced hyperlocomotion, and these effects were progressively increased across the 5-day period in both males and females, confirming the induction of ARI sensitization. On the challenge days, rats previously treated with ARI in adolescence also had significantly lower avoidance and lower PCP-induced hyperlocomotion than the previous vehicle rats, confirming the expression of ARI sensitization and its persistence into adulthood. More importantly, female rats made significantly more avoidances than males in both ARI and vehicle groups, indicating higher sensitivity to the acute and long-term effects of ARI. Further, on the OLZ and CLZ challenge days, prior ARI treatment seemed to increase sensitivity to OLZ exposure, however, this increase was not significant. Similarly, rats also showed an ARI sensitization to OLZ and CLZ on challenge days. Collectively, results from this experiment demonstrated a sex difference in response to ARI and enhanced inhibition of PCP-induced hyperlocomotion in animals that were pretreated with ARI as compared to controls.

AB - The present study investigated the potential sex differences in repeated aripiprazole (ARI) treatment-induced behavioral sensitization from adolescence to adulthood, and to determine whether ARI sensitization can be transferred to olanzapine (OLZ) and/or clozapine (CLZ) using the conditioned avoidance response (CAR) and phencyclidine-induced (PCP) hyperlocomotion tests of antipsychotic activity. Male and female Sprague-Dawley adolescence rats (P46) were first treated with ARI (10 mg/kg) for 5 consecutive days (P46–50) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion. After they became adults (> P68), rats were challenged with ARI (1.5 mg/kg, sc) (P70), OLZ (0.5 mg/kg, sc; P73), CLZ (5 mg/kg, sc; P76) and again with ARI (1.5 mg/kg, sc; P84) and tested for avoidance response and ARI-induced inhibition of PCP-induced hyperlocomotion again. During the drug treatment period in adolescence, repeated ARI treatment suppressed avoidance response, inhibited the PCP-induced hyperlocomotion, and these effects were progressively increased across the 5-day period in both males and females, confirming the induction of ARI sensitization. On the challenge days, rats previously treated with ARI in adolescence also had significantly lower avoidance and lower PCP-induced hyperlocomotion than the previous vehicle rats, confirming the expression of ARI sensitization and its persistence into adulthood. More importantly, female rats made significantly more avoidances than males in both ARI and vehicle groups, indicating higher sensitivity to the acute and long-term effects of ARI. Further, on the OLZ and CLZ challenge days, prior ARI treatment seemed to increase sensitivity to OLZ exposure, however, this increase was not significant. Similarly, rats also showed an ARI sensitization to OLZ and CLZ on challenge days. Collectively, results from this experiment demonstrated a sex difference in response to ARI and enhanced inhibition of PCP-induced hyperlocomotion in animals that were pretreated with ARI as compared to controls.

KW - Aripiprazole

KW - Conditioned avoidance response

KW - Development

KW - Phencyclidine

KW - Sensitization

KW - Sex difference

UR - http://www.scopus.com/inward/record.url?scp=85018501801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018501801&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2017.04.001

DO - 10.1016/j.pbb.2017.04.001

M3 - Article

C2 - 28389140

AN - SCOPUS:85018501801

VL - 156

SP - 39

EP - 47

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

ER -